title: Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
abstract: Zotepine, a new tricyclic compound, was investigated in 20 schizophrenic patients in two different dosage groups. Group I (n = 8) received Zotepine in a high dosage of 270 mg +/- 37 mg/die. The other group (group II; n = 12) received a low dosage of 168 mg +/- 15 mg/die. In both groups 2 patients dropped out before the end of the treatment period because of clinical deterioration. In both groups, Zotepine manifested a rapid antipsychotic effect, good tolerability, and sedative properties during the initial days. Additionally there was a stronger positive influence on negative symptoms in the group with low dosage treatment.
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D003988:Dibenzothiepins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D003988:Dibenzothiepins; C022172:zotepine